Medipost Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medipost Co., Ltd.
South Korean stem cell therapy company Medipost is speeding up the entry of flagship product Cartistem into global markets, with an initial focus on ASEAN countries and Japan and helped by regulators' allowance of early local trials to be waived on the back of strong Korean data.
In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.
Defymed Inc.’s MAILPAN (MAcro-encapsulation of PANcreatic Islets) is a bioartificial pancreas that can use a broader pool of cell types while protecting the cells from rejection by the immune system.
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced September through October 2014.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools